Benchmark Issues Positive Forecast for Omnicell (NASDAQ:OMCL) Stock Price

Omnicell (NASDAQ:OMCL) had its price target hoisted by Benchmark from $45.00 to $50.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. Benchmark currently has a buy rating on the stock.

Other research analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. Piper Sandler cut their price objective on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Omnicell currently has an average rating of “Hold” and a consensus target price of $43.00.

Omnicell Stock Down 0.1%

Shares of NASDAQ:OMCL opened at $43.49 on Tuesday. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 101.14, a price-to-earnings-growth ratio of 5.39 and a beta of 0.83. Omnicell has a 1-year low of $22.66 and a 1-year high of $47.70. The company’s fifty day moving average is $33.99 and its two-hundred day moving average is $31.68. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $33.25, for a total value of $129,010.00. Following the completion of the sale, the executive vice president directly owned 110,653 shares in the company, valued at $3,679,212.25. This represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.52% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Omnicell

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new stake in Omnicell during the second quarter valued at approximately $26,000. First Horizon Corp acquired a new position in shares of Omnicell in the 3rd quarter valued at $31,000. Farther Finance Advisors LLC increased its stake in Omnicell by 784.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after purchasing an additional 1,036 shares in the last quarter. GAMMA Investing LLC raised its holdings in Omnicell by 37.1% during the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock worth $50,000 after buying an additional 458 shares during the period. Finally, LSV Asset Management purchased a new stake in Omnicell during the third quarter valued at about $97,000. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.